52
Participants
Start Date
March 1, 2025
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2027
S1
PO, 40\~60mg,BID(d1-14,d22-35,two cycles)
Iparomlimab
IV infusion, 5mg/kg, q3w (Started within 8 weeks of completion of radiation)
Radiation
Concurrent Radiation, 1.8Gy/f, 28f;
RECRUITING
Tianjin Cancer Hospital, Tianjin
Tianjin Medical University Cancer Institute and Hospital
OTHER